[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"movement-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:movement-disorders":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,29,0,25,[9,42,73,103,124,153,177,215,239,274,312,354,376,395,421,454,477,502,535,564,589,619,659,687,713],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100558630","radiofrequency-rf-ablation-prospective-outcomes-study-for-central-nervous-system---rapid-for-cns-100558630",false,"NCT06553625","Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS","Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System","Inclusion Criteria:\n\n* Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU)\n* Signed a valid, IRB\u002FEC\u002FREB-approved informed consent form\n\nExclusion Criteria:\n\n* Meets any contraindications per locally applicable Directions for Use (DFU)\n* Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments","ALL",{"count":19,"type":20},200,"ESTIMATED","24 Months","OBSERVATIONAL","The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.",[25,26,27,28],"Parkinson Disease","Dystonia","Essential Tremor","Movement Disorders","RECRUITING","2026-06-10",{"date":32,"type":33},"2026-06-11","ACTUAL",{"date":35,"type":33},"2024-01-29",{"date":37,"type":20},"2035-12",{"name":39,"class":40},"Boston Scientific Corporation","INDUSTRY",4,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100622501","effects-of-targeted-temporal-interference-stimulation-of-cerebellar-nuclei-on-tremor-and-gait-disturbance-in-parkinsons-disease-patients-100622501","NCT07384442","Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's Disease Patients","Inclusion Criteria:\n\n* 1.Aged 50 years or older;\n* 2.Confirmed diagnosis of idiopathic Parkinson's disease (IPD) according to the 2015 MDS diagnostic criteria, with tremor and gait disturbance;\n* 3.Disease duration ≥2 years after diagnosis, stable condition, and ability to cooperate with study assessment and intervention;\n* 4.Stable medication dosage for at least 4 weeks prior to the trial;\n* 5.Good response to Levodopa therapy;\n* 6.Capable of independent walking (without assistive devices) for at least 5 minutes and able to complete gait testing independently.\n* 7.Signed informed consent form, with the participant or their legal guardian able to understand and willing to participate in this study.\n\nExclusion Criteria:\n\n* 1.History or confirmed diagnosis of severe mental disorders, such as depression, anxiety disorders, schizophrenia spectrum disorders, and bipolar disorder;\n* 2.The subject has clinically defined neurological conditions (assessed through self-report), including but not limited to: any disease potentially associated with increased intracranial pressure, space-occupying lesions, stroke history, transient ischemic attack (TIA) within the past two years, cerebral aneurysm, dementia, multiple sclerosis;\n* 3.Severe cognitive impairment, Mini-Mental State Examination (MMSE) score \\\u003C22, or inability to independently complete questionnaires;\n* 4.Inability to read or understand Chinese;\n* 5.Use of other neuromodulatory therapies within the past 3 months;\n* 6.Presence of musculoskeletal or orthopedic conditions (e.g., severe arthritis, recent fractures) that significantly interfere with gait or balance;\n* 7.Presence of metal implants (e.g., Deep Brain Stimulation, cardiac pacemakers) or contraindications for MRI\u002FTIS;\n* 8.Current use of medications that affect dopamine levels (e.g., antipsychotics);\n* 9.Severe cardiovascular disease or other unstable medical conditions that preclude physical exertion or study participation;","50 Years",{"count":50,"type":20},50,"INTERVENTIONAL",[53],"NA","The goal of this clinical trial is to explore the effects of cerebellar nuclei TIS stimulation on improving tremor and gait disorders in PD patients. Through randomized double-blind grouping, the differences in efficacy between TIS intervention and sham stimulation intervention for tremor and gait disorders in PD patients will be compared.",[56,28],"Parkinson's Disease",[56,58,28,59,60,61],"Cerebellar Nuclei","Tremor","Gait","Temporal Interference Stimulation","NOT_YET_RECRUITING","2026-06-09",{"date":30,"type":33},{"date":66,"type":20},"2026-08-19",{"date":68,"type":20},"2026-12-31",{"name":70,"class":71},"YangPan","OTHER",1,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":51,"phases":82,"briefSummary":83,"conditions":84,"keywords":91,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":72},"100579202","dyadic-mindfulness-for-people-with-parkinsons-disease-and-their-caregivers-100579202","NCT06821230","Dyadic Mindfulness for People With Parkinson's Disease and Their Caregivers","Enhancing Psychological Wellbeing and the Patient-caregiver Relationship Through Dyadic Mindfulness: A Randomized Controlled Trial in People With Parkinson's Disease and Their Caregivers","Inclusion Criteria of PwPD:\n\n* Chinese patients with idiopathic mild-moderate PD (as indicated by the Hoehn and Yahr Scale stages I-III: those with unilateral\u002Fbilateral symptoms, with\u002Fwithout postural instability who are able to walk\u002Fstand unassisted)\n* Aged ≥18 years\n\nInclusion Criteria of caregivers of PwPD:\n\n\\- Self-identified as the primary caregivers of their patient\n\nEither patient or caregiver needs to experience at least mild negative emotions (as indicated by the 21-item Depression, Anxiety and Stress Scale \\[DASS21\\] score of Depression subscale ≥10, Anxiety subscale ≥8, or Stress subscale ≥15)\n\nBoth need to be able to communicate in Cantonese and provide written consent.\n\nExclusion Criteria:\n\n* Engage in regular supervised mind-body practices such as Tai Chi, yoga, or other forms of mindfulness training (\\>2 times per week)\n* Have a pre-existing acute psychotic disease\n* Currently participating in any other behavioral or pharmacological trial\n* Have significant cognitive impairment, as indicated by an Abbreviated Mental Test score≤ 6\n* Have other contraindications that may limit their full participation (e.g., severe hearing\u002Fvision impairment)","18 Years",{"count":19,"type":20},[53],"The proposed two-arm randomized waitlist-controlled trial will use a mixed-methods design to investigate the effects of dyadic mindfulness on physio-psycho-spiritual outcomes in people with Parkinson's Disease (PwPD) and their family caregivers. One hundred Chinese patient-caregiver dyads will be randomized to receive eight weekly 90-minute dyadic mindfulness sessions or usual care. Outcome measures include negative emotions (primary outcome), patient-caregiver relationship, mindfulness, HRQOL, gut microbiome, PD-related symptoms, and caregiving burden. An actor-partner interdependence model will be used to explore the interactions of treatment effects within the dyads. The dyads will be assessed at baseline(T0), post-intervention(T1), and 4-months post-intervention(T2). The investigators will also invite 25 dyads to attend in-depth interviews exploring their experiences, perceived changes, and factors attributable to the effectiveness\u002Fineffectiveness of the intervention. Generalized linear mixed-effects (GLME) with intention-to-treat analysis will be used to compare the changes in outcomes over time within and between the two arms. The findings will be triangulated to provide a comprehensive evaluation of the intervention's effectiveness. This study will generate rigorous scientific evidence to inform the application of dyadic mindfulness as a public health practice preventing the progression of psychological distress in PwPD and caregivers to clinically severe levels. Its self-help nature also enriches the primary care for this clinical cohort.",[85,86,28,87,88,89,90],"Mindfulness","Caregivers","Neurodegenerative Disease","Dyadic Intervention","Psychosocial Health","Parkinsons Disease",[92,85,93],"Parkinsons disease","dyadic care","2026-05-28",{"date":96,"type":33},"2026-06-01",{"date":98,"type":33},"2025-02-11",{"date":100,"type":20},"2027-06-30",{"name":102,"class":71},"The University of Hong Kong",{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":72},"100502448","cognitive-decline-following-deep-brain-stimulation-100502448","NCT05822388","Cognitive Decline Following Deep Brain Stimulation","A Neural Basis for Cognitive Decline Following Deep Brain Stimulation","PD Participants\n\nInclusion Criteria:\n\n* Subjects above 18 years of age\n* Subjects who will undergo DBS surgery as part of their clinical care for PD\n\nExclusion Criteria:\n\n* Uncorrected visual or hearing impairments, as indicated by self-report\n* Individuals who are pregnant or expect to become pregnant during the course of the study\n* Individuals with claustrophobia, or the inability to lie supine position in the MRI scanner\n* COPD with oxygen dependence\n* Non-MRI compatible metal implants (surgical clips or staples, cardiac pacemakers etc.)\n\nNon-PD Control Participants\n\nInclusion Criteria:\n\n* Subjects above 18 years of age\n* Age matched to participants in PD group\n\nExclusion Criteria:\n\n* Diagnosis of Parkinsons Disease or other movement disorder\n* Untreated neuropsychiatric disorders\n* Uncorrected visual or hearing impairments, as indicated by self-report\n* Individuals who are pregnant or expect to become pregnant during the course of the study\n* Individuals with claustrophobia, or the inability to lie supine position in the MRI scanner\n* COPD with oxygen dependence\n* Non-MRI compatible metal implants (surgical clips or staples, cardiac pacemakers etc.)",true,{"count":112,"type":20},80,"This research study aims to identify MRI-based brain biomarkers that predict an individual's response to Deep Brain Stimulation (DBS). In particular, this study will focus on changes in cognition associated with DBS. A total of 55 participants with Parkinson's Disease planning to undergo DBS will be recruited from MUSCs Clinical DBS Program. Participants will undergo four visits, including a 1-hour screening visit, a 1.5-hour pre-DBS MRI scanning visit, and a 3.5-hour post-DBS cognitive assessment visit. In addition control participants without Parkinson's Disease will be recruited to undergo MRI scanning and cognitive assessments.",[25,28],"2026-05-27",{"date":117,"type":33},"2026-05-29",{"date":119,"type":33},"2023-04-01",{"date":121,"type":20},"2027-03-31",{"name":123,"class":71},"Medical University of South Carolina",{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":51,"phases":134,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":41},"100592873","long-read-genome-sequencing-for-the-molecular-diagnosis-of-dystonia-100592873","NCT06999096","Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia","Evaluation of the Value of Long-read Genome Sequencing for the Molecular Diagnosis of Dystonia: a Prospective Multicenter Study","GenoDYT","Inclusion criteria - Index case:\n\n* Index case affected by familial dystonia (≥1 first-degree relative affected) and\u002For sporadic early-onset dystonia (symptom onset before age 50), meeting the criteria of the PFMG-2025 program.\n* Index case who has undergone short-read genome sequencing, which did not lead to a molecular diagnosis.\n* Ability to understand and sign informed consent by the index case and\u002For their parents or legal guardians for patients under 18 years of age.\n* Availability of a blood sample from the index case and at least two relatives, either affected or unaffected.\n\nInclusion criteria - Relatives:\n\n* Symptomatic or asymptomatic relative of an index case, who has also undergone short-read genome sequencing without a conclusive molecular diagnosis.\n* Ability to understand and sign informed consent.\n\nExclusion criteria:\n\n* Index case or relatives who are not affiliated with or not beneficiaries of a social security scheme.\n* Index case and their parents presenting with a condition that, in the opinion of the investigator, would contraindicate participation in the study.\n* Suspected non-genetic etiology (e.g., perinatal hypoxic-ischemic injury, kernicterus, history of severe head trauma or central nervous system infection).",{"count":133,"type":20},150,[53],"Dystonia is a motor disorder caused by involuntary, intermittent, or sustained muscle contractions, leading to abnormal movements or postures. It can affect any body region and often results in significant functional disability and healthcare burden. Although its familial nature was recognized early on, the advent of high-throughput DNA sequencing has dramatically increased the identification of dystonia-associated genes. Dystonia now encompasses all modes of inheritance-autosomal dominant (e.g., TOR1A, KMT2B), autosomal recessive, X-linked, and mitochondrial-and over 100 genes have been implicated. Many forms involve structural variants (SVs) or copy number variations (CNVs), which are challenging to detect using standard short-read sequencing (srWGS).\n\nMolecular diagnosis is essential, ending the diagnostic odyssey and enabling genetic counseling, prognosis, reproductive planning, and-in some cases-targeted therapies. For instance, GNAO1-related dystonia may respond to deep brain stimulation, while dopa-responsive dystonia benefits from levodopa.\n\nDespite advances, srWGS has key limitations, especially for detecting repeat expansions, SVs, and phasing alleles. This likely explains the low diagnostic yield in dystonia compared to other neurological disorders, with over 70% of cases remaining unsolved.\n\nLong-read sequencing (lrWGS), such as Oxford Nanopore technology, overcomes many of these challenges by reading native DNA fragments thousands of bases long. It enables comprehensive detection of SNVs, indels, SVs, CNVs, methylation changes, and repeat expansions-including known and newly discovered pathogenic expansions (e.g., in NOTCH2NLC). It also allows phasing without parental samples, which is crucial in recessive cases.\n\nThe investigators propose that lrWGS could significantly increase the diagnostic yield in dystonia, improving patient care, enabling appropriate genetic counseling, and paving the way for personalized treatment strategies.",[26,28,137,138],"Combined Dystonia","Complex Dystonia",[26,140,141,142,143],"Genome Sequencing","Long-read Sequencing","Molecular diagnosis","Neurogenetics","2026-05-19",{"date":146,"type":33},"2026-05-20",{"date":148,"type":20},"2026-04-22",{"date":150,"type":20},"2030-08",{"name":152,"class":71},"University Hospital, Strasbourg, France",{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":110,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":175,"locationsCount":72},"100495830","validating-a-new-machine-learned-accelerometer-algorithm-using-doubly-labeled-water-100495830","NCT05736302","Validating a New Machine-Learned Accelerometer Algorithm Using Doubly Labeled Water","ValiDLW","Inclusion Criteria:\n\n* must be 18+ years of age\n* be able to ambulate on own, unassisted, on a regular basis\n* speak and read English\n* must have access to a working smart phone and a computer with internet access\n\nExclusion Criteria:\n\n* wheelchair reliant\n* assistive walking device reliant (cannot walk for at least 50 feet without an assistive device)\n* diagnosed uncontrolled hypertension (above 160\u002F100 mgHg)\n* diagnosed cognitive impairment or inability to follow study procedures such as Alzheimer's disease or dementia\n* cannot take metabolic altering medications\n* cannot be pregnant\n* cannot be breastfeeding\n* cannot use supplemental oxygen\n* cannot completed required study activities for any reason\n* cannot have a resting heart rate \\> 100 bpm or a resting blood pressure \\> 160 mgHg during Visit 1\n* cannot weigh more than 450 lbs",{"count":161,"type":20},125,"The purpose of this study is to validate previously developed physical function-clustered specific machine-learned accelerometer algorithms to estimate total daily energy expenditure (TDEE) in individuals with general movement and functional limitations.",[28,164],"Energy Metabolism",[166,167,168],"Doubly labeled water (DLW)","Total Daily Energy Expenditure (TDEE)","Accelerometry","2026-04-27",{"date":171,"type":33},"2026-05-04",{"date":173,"type":33},"2023-03-14",{"date":68,"type":20},{"name":176,"class":71},"University of Wisconsin, Milwaukee",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":110,"sex":17,"minAge":80,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":51,"phases":187,"briefSummary":188,"conditions":189,"keywords":198,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":72},"100453331","non-invasive-bci-controlled-assistive-devices-100453331","NCT05183152","Non-invasive BCI-controlled Assistive Devices","Non-invasive Brain-computer Interfaces for Control of Assistive Devices","Inclusion Criteria:\n\n1. Able-bodied participants:\n\n   * good general health\n   * normal or corrected vision\n   * no history of neurological\u002Fpsychiatric disease\n   * ability to read and understand English (Research Personnel do not speak Spanish)\n2. Subjects with motor disabilities\n\n   * motor deficits due to: unilateral and bilateral stroke \u002F spinal cord injury \u002F motor neuron diseases (i.e. amyotrophic lateral sclerosis, spino-cerebellar ataxia, multiple sclerosis) \u002F muscular diseases (i.e. myopathy) \u002F traumatic or neurological pain \u002F movement disorders (i.e. cerebral palsy) \u002F orthopedic \u002F traumatic brain injury \u002F brain tumors\n   * normal or corrected vision\n   * ability to read and understand English\n   * ability to provide informed consent\n\nExclusion Criteria:\n\n1. Subjects with motor disabilities\n\n   * short attentional spans or cognitive deficits that prevent the subject from concentrating during the whole experimental session\n   * heavy medication affecting the central nervous system (including vigilance)\n   * concomitant serious illness (e.g., metabolic disorders)\n2. All participants\n\n   * factors hindering EEG\u002FEMG acquisition and the delivery of non-invasive electrical stimulation (e.g., skin infection, wounds, dermatitis, metal implants under electrodes)\n   * criteria identified in safety guidelines for MRI and TMS, in particular metallic implants","80 Years",{"count":186,"type":20},100,[53],"Injuries affecting the central nervous system may disrupt the cortical pathways to muscles causing loss of motor control. Nevertheless, the brain still exhibits sensorimotor rhythms (SMRs) during movement intents or motor imagery (MI), which is the mental rehearsal of the kinesthetics of a movement without actually performing it. Brain-computer interfaces (BCIs) can decode SMRs to control assistive devices and promote functional recovery. Despite rapid advancements in non-invasive BCI systems based on EEG, two persistent challenges remain: First, the instability of SMR patterns due to the non-stationarity of neural signals, which may significantly degrade BCI performance over days and hamper the effectiveness of BCI-based rehabilitation. Second, differentiating MI patterns corresponding to fine hand movements of the same limb is still difficult due to the low spatial resolution of EEG. To address the first challenge, subjects usually learn to elicit reliable SMR and improve BCI control through longitudinal training, so a fundamental question is how to accelerate subject training building upon the SMR neurophysiology. In this study, the investigators hypothesize that conditioning the brain with transcutaneous electrical spinal stimulation, which reportedly induces cortical inhibition, would constrain the neural dynamics and promote focal and strong SMR modulations in subsequent MI-based BCI training sessions - leading to accelerated BCI training. To address the second challenge, the investigators hypothesize that neuromuscular electrical stimulation (NMES) applied contingent to the voluntary activation of the primary motor cortex through MI can help differentiate patterns of activity associated with different hand movements of the same limb by consistently recruiting the separate neural pathways associated with each of the movements within a closed-loop BCI setup. The investigators study the neuroplastic changes associated with training with the two stimulation modalities.",[190,191,192,193,194,195,196,28,197],"Motor Disorders","Healthy","Spinal Cord Injuries","Muscular Diseases","Motor Neuron Disease","Stroke","Traumatic Brain Injury","Multiple Sclerosis",[199,200,201,202,203,204,205,206],"motor deficits","able-bodied, healthy","unilateral and bilateral stroke","spinal cord injury","motor neuron diseases","muscular diseases (i.e. myopathy)","traumatic or neurological pain","movement disorders",{"date":208,"type":33},"2026-05-01",{"date":210,"type":33},"2021-06-16",{"date":212,"type":20},"2028-12-30",{"name":214,"class":71},"University of Texas at Austin",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":221,"maxAge":222,"enrollmentInfo":223,"targetDuration":225,"studyType":22,"phases":4,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":238},"100480685","a-post-approval-registry-for-exablate-4000-type-10-and-type-11-for-unilateral-pallidotomy-for-the-treatment-of-advanced-idiopathic-parkinsons-disease-with-medication-refractory-moderate-to-severe-motor-complications-100480685","NCT05539196","A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications","Inclusion Criteria:\n\n* Men and women, age 30 years and older.\n* Subject undergoing a planned an Exablate procedure for their Parkinson's Disease with Motor Complications per local institution standard of care.\n* Subject is willing to cooperate with the Registry requirements including compliance with the regimen and completion of all Registry visits.\n* Subject has signed and received a copy of the approved informed consent form.\n\nExclusion Criteria:\n\n* Subject does not agree to participate or is unlikely to participate for the entirety of the Registry.","30 Years","99 Years",{"count":224,"type":20},60,"5 Years","This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years. The proposed registry will enroll 60 subjects and will be conducted at approximately 10 centers worldwide.",[28,228,90],"Neurology","2026-03-18",{"date":231,"type":33},"2026-03-20",{"date":233,"type":33},"2023-01-23",{"date":235,"type":20},"2029-07-31",{"name":237,"class":40},"InSightec",5,{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":17,"minAge":247,"maxAge":80,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":249,"conditions":250,"keywords":258,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":72},"100561089","a-multicenter-pediatric-deep-brain-stimulation-registry-100561089","NCT06585618","A Multicenter Pediatric Deep Brain Stimulation Registry","Multicenter Pediatric Deep Brain Stimulation Registry","DBS-R","Inclusion Criteria:\n\n* Female or male patients between ages of 0-18 years.\n* Having received or scheduled to receive DBS for any neurological movement disorder.\n* Parents or legal guardians are able to provide written consent for prospective enrollment.","0 Years",{"count":186,"type":20},"There is limited data on outcomes for children who have undergone deep brain stimulation (DBS) for movement disorders, and individual centers performing this surgery often lack sufficient cases to power research studies adequately. This study aims to develop a multicenter pediatric DBS registry that allows multiple sites to share clinical pediatric DBS data. The primary goals are to enable large-scale, well-powered analyses of the safety and efficacy of DBS in the pediatric population and to further explore and refine DBS as a therapeutic option for children with dystonia and other hyperkinetic movement disorders. Given the current scarcity of evidence available to clinicians, this centralized multicenter repository of clinical data is critical for addressing key research questions and improving clinical practice for pediatric DBS.",[26,251,252,253,254,255,256,28,257],"Epilepsy in Children","Cerebral Palsy","Tourette Syndrome","Obsessive-Compulsive Disorder","Neurologic Disorder","Movement Disorders in Children","Deep Brain Stimulation",[257,259,260,261,262,263,264,265],"DBS","movement disorder","movement disorders in children","dystonia","chorea","dyskinesia","epilepsy","2026-03-16",{"date":229,"type":33},{"date":269,"type":33},"2024-07-30",{"date":271,"type":20},"2029-07-30",{"name":273,"class":71},"Boston Children's Hospital",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":17,"minAge":247,"maxAge":80,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":282,"conditions":283,"keywords":290,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":72},"100561088","a-retrospective-survey-based-multicenter-study-to-delineate-the-molecular-and-phenotypic-spectrum-of-epilepsy-dyskinesia-syndromes-100561088","NCT06585605","A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes","Inclusion Criteria:\n\n* Children between 0 - 18 years of age with a movement disorder and a pathogenic or likely pathogenic variant in one of the genes of interest:\n\nAARS2 ALG13 AP3B2 AP4B1 AP4E1 AP4M1 AP4S1 ARX ATP1A3 CACNA1A CACNA1E CACNA2D2 CDKL5 CSTB DARS2 DLAT DLD DNM1 EARS2 EPG5 FARS2 FOXG1 FRRS1L GABRA1 GABRA2 GABRB2 GABRB3 GABRG2 GRIA2 GRIA4 GRIN1 GRIN2A GRIN2B GRIN2D GNAO1 HARS2 HNRNPU IQSEC2 KCNA2 KCNB1 KCNC1 KCNMA1 KCNQ2 KCNQ3 KCNT1 LARS2 MECP2 MEF2C MTND5 MTTL1 MTTK NARS2 NHLRC1 PDE10A PDE2 PCDH12 PCDH19 PDK3 PIGP PIGQ PIGS PIGN POLG PDHA1 PDHB PDHX PRRT2 PURA RHOBTB2 SCN1A SCN1B SCN2A SCN8A SCN9A SLC13A5 SLC1A2 SLC2A1 SLC25A22 SMCA1 SNP14 ST3GAL3 STXBP1 SPTAN1 SYNGAP1 TBC1D24 TBL1WL1 TARS2 UBA5 UBE3A VAMP2 VARS2 WARS2 WDOX WDR45 YIF1B YWHAG\n\nExclusion Criteria:\n\n* Not having such diagnosis and\u002For not presenting a movement disorder.",{"count":281,"type":20},500,"The Epilepsy-Dyskinesia Study aims to advance the understanding of the clinical and molecular spectrum of epilepsy-dyskinesia syndromes, monogenic diseases that cause both movement disorders and epilepsy. Addressing challenges in rare disease research -such as small, geographically dispersed patient populations and a lack of standardized protocols- the study employs a multinational retrospective survey endorsed by the International Parkinson and Movement Disorder Society. This survey seeks to collect comprehensive data on clinical features, disease progression, age of onset, genetic variants, and concurrent neurological conditions, standardizing data collection across countries to provide a unified understanding of these conditions. Through retrospective review and molecular data analysis, the study aims to identify patterns and correlations between movement and seizure disorders, uncovering genotype-phenotype relationships. The initiative\\'s goals are to enhance understanding of epilepsy-dyskinesia syndromes, inform precision medicine approaches, and foster international collaboration.",[251,284,256,255,285,286,287,288,289,28],"Dyskinesias","Chorea","Myoclonus","Ataxia","Epilepsy","Dystonia Disorder",[291,206,292,264,262,293,294,295,296,297,298,299,300,301,302,303,304,305],"epilepsy-dyskinesia syndrome","epileptic encephalopathy","neurogenetics","PRRT2","ATP1A3","MECP2","CACNA1A","CDKL5","FOXG1","GNAO1","SCN1A","SCN8A","SLC2A1","STXBP1","UBA5",{"date":229,"type":33},{"date":308,"type":33},"2024-07-01",{"date":310,"type":20},"2029-12-31",{"name":273,"class":71},{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":17,"minAge":319,"maxAge":221,"enrollmentInfo":320,"targetDuration":225,"studyType":22,"phases":4,"briefSummary":321,"conditions":322,"keywords":327,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":72},"100466506","hereditary-spastic-paraplegia-genomic-sequencing-initiative-hspseq-100466506","NCT05354622","Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)","Investigating the Genetic Basis of Hereditary Spastic Paraplegia","Inclusion Criteria:\n\n* Clinical diagnosis of progressive spasticity","1 Month",{"count":19,"type":20},"The purpose of the HSP Sequencing Initiative is to better understand the role of genetics in hereditary spastic paraplegia (HSP) and related disorders. The HSPs are a group of more than 80 inherited neurological diseases that share the common feature of progressive spasticity. Collectively, the HSPs present the most common cause of inherited spasticity and associated disability, with a combined prevalence of 2-5 cases per 100,000 individuals worldwide.\n\nIn childhood-onset forms, initial symptoms are often non-specific and many children may not receive a diagnosis until progressive features are recognized, often leading to a significant diagnostic delay. Genetic testing in children with spastic paraplegia is not yet standard practice. In this study, the investigators hope to identify genetic factors related to HSP. By identifying different genetic factors, the investigators hope that over time we can develop better treatments for sub-categories of HSP based on cause.",[323,324,325,326,194,28],"Hereditary Spastic Paraplegia","Neurodegenerative Diseases","Pediatric Disorder","Spasticity, Muscle",[323,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347],"Neurodegenerative disease","Spasticity","SPG3a","SPG4","SPG11","SPG15","SPG26","SPG47","SPG50","SPG51","SPG52","Complex hereditary spastic paraplegia","Early Onset hereditary spastic paraplegia","Movement disorder","Adaptor protein complex 4","Neurogenetic disorder","Genetic Disease","Muscle Spasticity","Neurodevelopmental disorders","Musculoskeletal Disease",{"date":229,"type":33},{"date":350,"type":33},"2022-04-25",{"date":352,"type":20},"2027-04-29",{"name":273,"class":71},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":51,"phases":362,"briefSummary":363,"conditions":364,"keywords":365,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":72},"100367197","neurophysiological-behavioral-and-cognitive-networks-in-movement-disorders-100367197","NCT04061135","Neurophysiological, Behavioral, and Cognitive Networks in Movement Disorders","Inclusion Criteria:\n\n* Eligible for DBS surgery based on multi-disciplinary consensus review\n* Have a diagnosis of Parkinson's disease or Essential Tremor\n* A minimum of 18 years of age\n* Willingness to participate in the paradigms described in the protocol\n\nExclusion Criteria:\n\n* Inability to provide full and informed consent\n* Are not surgical candidates due to co-morbid conditions or pregnancy\n* Have not undergone an adequate trial of conservative medical management\n* Have a clinical presentation for which DBS surgery is not indicated\n* Are not able to participate in study-related activities",{"count":361,"type":20},90,[53],"The purpose of this study is to investigate the brain activity associated with motor and non-motor symptoms of movement disorders, including Parkinson's disease (PD) and essential tremor. These movement disorders commonly have significant non-motor features, such as depression, cognitive and memory impairment, decreased attention, speech and language disturbances, and slower processing speeds. The investigators are interested in the brain activity associated with these motor and non-motor symptoms, and propose to investigate changes in brain activity while the investigators perform recordings of the surface and deep structures of the brain, in addition to the typical recordings the investigators perform, during routine deep brain stimulation (DBS) surgery.",[28],[366],"Parkinson's disease","2026-03-14",{"date":369,"type":33},"2026-03-17",{"date":371,"type":33},"2019-09-01",{"date":373,"type":20},"2029-03-31",{"name":375,"class":71},"University of Alabama at Birmingham",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":51,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":72},"100581301","neurophysiology-of-the-basal-ganglia-thalamus-and-cerebellum-in-patients-with-movement-disorders-100581301","NCT06848530","Neurophysiology of the Basal Ganglia, Thalamus, and Cerebellum in Patients With Movement Disorders","Inclusion Criteria:\n\n* Patients 18 years of age and above\n* Any patient who has been diagnosed by a movement disorders neurologist with one of the following movement disorders:\n* Parkinson's disease\n* Dystonia\n* Tremor, including essential tremor\n* Cerebellar ataxia\n* Other hyperkinetic movement disorders, such as chorea and tics\n\nExclusion Criteria:\n\n\\- Patients with dementia",{"count":186,"type":20},[53],"The research study is being conducted to better understand parts of the human brain called the cortex, basal ganglia, thalamus, and cerebellum in patients with movement disorders (such as Parkinson's disease, essential tremor, dystonia, or ataxia). These brain structures are involved in movement disorders. This study attempts to better understand the brain electrical activity associated with these disorders, both in patients with and without deep brain stimulation (DBS). Recordings are made from the scalp with a noninvasive electrode and\u002For through the DBS stimulator if the participant has a stimulator model that is able to sense brain activity. These recordings are analyzed along with measures of movement disorder symptoms to identify brain signal signatures of symptoms.",[28],"2026-03-08",{"date":388,"type":33},"2026-03-11",{"date":390,"type":33},"2025-12-10",{"date":392,"type":20},"2030-04",{"name":394,"class":71},"University of Pennsylvania",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":51,"phases":404,"briefSummary":405,"conditions":406,"keywords":408,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":72},"100510450","leg-stretching-using-an-exoskeleton-on-demand-for-people-with-spasticity-100510450","NCT05926596","Leg Stretching Using an Exoskeleton on Demand for People With Spasticity","Leg Stretching Using a Controllable Wearable Exoskeleton on Demand for People With Spasticity","Inclusion Criteria:\n\n* Veteran individuals with spasticity due to spinal cord injury (SCI) at least 6 months post SCI\n* Capable of providing informed consent and reporting age, gender, and neurological condition\n* Neurologically stable (\\>6 months post-SCI) and can wear the device and the sensors, provide written informed consent, and follow instruction\n\nExclusion Criteria:\n\n* Participants should not experience another neurological disorder except their primary diagnosed neurological condition (spinal cord injury)\n* Participants should not be pregnant\n* Participants should weigh less than 300 lbs\n* Participants should not have experienced signs of hip\u002Fknee pain during the past 2-3 weeks that limits mobility (i.e., reaching, walking, lifting, etc.)\n* Participants should be recovered from any previous surgical interventions, joint injuries, muscle strain, or extreme muscle soreness following surgery\n* Participants should not take medications known to affect bone metabolism, muscle strength or cardiovascular performance or have any ailments causing high fever, high blood pressure, or high heart rate",{"count":403,"type":20},10,[53],"The purpose of this research study is to develop a protocol using a fully wearable, portable lower-limb exoskeleton for improving leg and walking function in people with movement disorders. The study investigates the effects of wearing the device during a set of experiments including leg stretching, treadmill walking and overground walking in muscle activity, joint motion, and gait performance. The goal is to develop an effective lower-limb strategy to restore lost leg function (e.g., range of motion) and gait ability, and improve quality of life in people with movement deficits following a neurological disorder.",[329,28,407],"Spinal Cord Injury",[409,410],"exoskeleton","spasticity","2026-02-19",{"date":413,"type":33},"2026-02-23",{"date":415,"type":33},"2026-02-09",{"date":417,"type":20},"2026-10-30",{"name":419,"class":420},"VA Office of Research and Development","FED",{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":428,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":51,"phases":431,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":446,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":72},"100522879","moderate-versus-high-volume-light-moderate-intensity-exercise-for-people-with-moderate-parkinsons-disease-100522879","NCT06088355","Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease","HI-LITE","Inclusion Criteria:\n\nParticipants recruited for this study will be age 40 and older with diagnosis of \"definite\" PD based upon established criteria (Hughes, Daniel et al. 1992) and determined by a board-certified neurologist with specialty training in movement disorders. Individuals must have presented with asymmetric symptoms that included at least 3 of the cardinal signs of PD (rigidity, bradykinesia, tremor, postural instability), and must show clear symptomatic benefit (e.g., alleviated rigidity, bradykinesia, and tremor) from antiparkinsonian medications, e.g., levodopa (Kempster, Williams et al. 2007). They should be in H\\&Y stages 2, 2.5 and 3, and receive a Montreal Cognitive Assessment (MoCA) score \\>17 (Litvan, Goldman et al. 2012). Age 40 is the upper limit for young onset PD. We will not recruit individuals with a history of significant alcohol or drug use, nor habitual users of antipsychotics. We will observe patients while OFF their antiparkinsonian medications to avoid dyskinesia, and medication fluctuations that may impact neurophysiology and motor examination. We have successfully observed patients while OFF in several previous trials. The following inclusion criteria apply:\n\n* MoCA score \\>17\n* Able to walk with or without an assistive device at least 10 feet\n* Best corrected\u002Faided acuity better than 20\u002F70 in the better eye\n* Willingness to be randomized to a treatment group\n* H\\&Y stages 2, 2.5 and 3\n* Show clear symptomatic benefit (e.g., alleviated rigidity, bradykinesia, and tremor) from antiparkinsonian medications\n* Fluent in English to be able to comprehend and participate; older than 40 years; Diagnosis of definite Parkinson's disease by board certified Movement Disorders Neurologist, using standardized UK Brain Bank criteria\n\nExclusion Criteria:\n\nParticipants recruited for this study will be age 40 and older with diagnosis of \"definite\" PD based upon established criteria (Hughes, Daniel et al. 1992) and determined by a board-certified neurologist with specialty training in movement disorders. Individuals must have presented with asymmetric symptoms that included at least 3 of the cardinal signs of PD (rigidity, bradykinesia, tremor, postural instability), and must show clear symptomatic benefit (e.g., alleviated rigidity, bradykinesia, and tremor) from antiparkinsonian medications, e.g., levodopa (Kempster, Williams et al. 2007). They should be in H\\&Y stages 2, 2.5 and 3, and receive a Montreal Cognitive Assessment (MoCA) score \\>17 (Litvan, Goldman et al. 2012). Age 40 is the upper limit for young onset PD. We will not recruit individuals with a history of significant alcohol or drug use, nor habitual users of antipsychotics. The following exclusion criteria apply:\n\n* Untreated Major Depression and major psychiatric illness\n* History of stroke, or traumatic brain injury\n* Pure-tone threshold average sensitivity at 0.5, 1.0,and 2.0 kHz exceeds 40 dB\n* Alcohol abuse and\u002For use of antipsychotics\n* Planning to leave the area for \\>1 month during the study time period.\n* Taking moderate to high doses of beta-blockers with a resting heart rate below 60 beats\u002Fmin given that exercise intensity is measured through target heart rate.\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina\n* Other significant co-morbid disease that would impair ability to participate in the exercise-based intervention, e.g. renal failure on hemodialysis, excessive alcohol use (\\>14 drinks per wk)","40 Years",{"count":430,"type":20},123,[53],"Veterans with mid to later stage Parkinson's disease (PD) may not be able to work out as hard as they need to, to prevent brain cell loss. Maybe they could work out longer and more frequently to make up for this during their good times and good weeks and then rest during the bad weeks. The investigators will compare how effective working out a lot one week per month with a break of three weeks is to continuously exercising weekly with no breaks in people with mid stage PD. The investigators will look at how fast participants walk per minute, whether they become more physically active, the biochemicals in their blood, and at how stiff their blood vessels are before and after the exercise.",[25,28,434],"Neurodegeneration",[436,437,438,439,440,441,442,443,444,445,366],"dance","walk","Neurodegenerative","aging","exercise","high volume","frequency","intensity","duration","biomarkers","2026-02-02",{"date":448,"type":33},"2026-02-05",{"date":450,"type":33},"2025-01-25",{"date":452,"type":20},"2029-06-02",{"name":419,"class":420},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":461,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":476},"100368019","abbott-dbs-post-market-study-of-outcomes-for-indications-over-time-100368019","NCT04071847","Abbott DBS Post-Market Study of Outcomes for Indications Over Time","ADROIT","Inclusion Criteria:\n\n1. Subject is scheduled for a new implant or IPG device replacement surgery with a market-released Abbott DBS system within 180 days.\n2. Subject, or a legally acceptable representative, must provide written informed consent prior to any study-related procedure.\n\nExclusion Criteria:\n\n1. Subject is currently enrolled or plans to enroll in an investigational study that may confound the results of this study.\n2. Subject has anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the study or to comply with follow-up requirements, or impact the scientific soundness of the study results.\n3. Study center is located in the United States, and indication for DBS implant is not Parkinson's disease or disabling tremor.\n4. Study center is located in the United States, and the intended lead implant location is not at, or in close proximity to, the STN, GPi, or VIM thalamus.",{"count":462,"type":20},1000,"The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.",[28,25,27,59,26,465,466],"Primary Dystonia","Secondary Dystonia","2026-01-07",{"date":469,"type":33},"2026-01-08",{"date":471,"type":33},"2019-11-26",{"date":473,"type":20},"2030-09",{"name":475,"class":40},"Abbott Medical Devices",48,{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":482,"acronym":4,"eligibilityCriteria":483,"healthyVolunteers":110,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":484,"targetDuration":4,"studyType":51,"phases":485,"briefSummary":486,"conditions":487,"keywords":490,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":493,"lastUpdatePostDateStruct":494,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":72},"100611154","towards-restoring-complex-movement-after-paralysis-algorithm-development-with-healthy-participants-100611154","NCT07236892","Towards Restoring Complex Movement After Paralysis: Algorithm Development With Healthy Participants","Restoring Complex Movement and Locomotion After Paralysis Through Collaborative Copilots: Algorithm Development With Healthy Participants","Inclusion Criteria:\n\n* Fluent in the English language\n\nExclusion Criteria:\n\n* Neurological injury or disease that results in functional paralysis",{"count":50,"type":20},[53],"Participants will perform experiments with non-invasive activity recordings. The study will record from multiple non-invasive signal sources that reflect motor intent that may include: electroencephalography (EEG), electromyography (EMG), functional near infrared spectroscopy (fNIRS), inertial measurement units (IMUs), eye movements, pupil size, and speech. Participants will wear all or a subset of these sensors and be asked to perform, imagine, or attempt movements or speech. The recorded sensor signals will be decoded to help guide an end effector, which may be a computer, robotic arm, wheelchair, or other assistive device.\n\nThese experiments present minimal risk and participants may withdraw participation at any time for any reason. Participants may return for additional experiments if desired and to perform additional comparisons. If a participant withdraws during a comparison, another participant will be recruited to complete collection of data for that comparison.",[28,488,489],"Neurorehabilitation","Non-invasive Activity Recording",[491,492],"Machine Learning","Algorithm Development","2025-12-22",{"date":495,"type":33},"2025-12-24",{"date":497,"type":33},"2025-11-26",{"date":499,"type":20},"2029-12-01",{"name":501,"class":71},"University of California, Los Angeles",{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":110,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":510,"targetDuration":225,"studyType":22,"phases":4,"briefSummary":511,"conditions":512,"keywords":515,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":525,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":534},"100449836","target-als-biomarker-study-longitudinal-biofluids-clinical-measures-and-at-home-measures-100449836","NCT05137665","Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures","Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At - Home Measures","TALSLB","ALS Participants:\n\n1. Age 18 or older.\n2. A diagnosis of ALS in accordance with Gold Coast criteria.\n3. Full Vital Capacity (FVC) of ≥30% or at the discretion of the Principal Investigator for the participant's predicted value for gender, height, and age at the time of screening.\n4. Ability to provide informed consent and understand the purpose and risks of the study.\n5. Ability to comply with study procedures and assessments, in the opinion of the Principal Investigator.\n\nHealthy Control Participants:\n\n1. Age 18 or older.\n2. No history of neurological disease, in the opinion of the Principal Investigator.\n3. No known ALS- associated genetic mutations at the time of consent.\n4. Ability to provide informed consent and understand the purpose and risks of the study.\n5. Ability to comply with study procedures and assessments, in the opinion of the Principal Investigator.",{"count":462,"type":20},"The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-weekly in a subset of participants. ALS participants will be asked to come to the clinic for 5 study visits approximately every 4 months. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.",[513,28,514,194],"Amyotrophic Lateral Sclerosis","Degenerative Disorder",[513,516,517,518,519,520,521,522,523,524],"ALS Amyotrophic Lateral Sclerosis","Target ALS","Longitudinal Biofluids","Barrow Neurological Institute","New York Genome Center","Biofluids Biorepository","Genomic-wide association studies","observational study","Biofluid Samples","2025-11-20",{"date":527,"type":33},"2025-11-21",{"date":529,"type":33},"2021-06-01",{"date":531,"type":20},"2031-12-31",{"name":533,"class":71},"Target ALS Foundation, Inc.",12,{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":110,"sex":17,"minAge":80,"maxAge":542,"enrollmentInfo":543,"targetDuration":4,"studyType":51,"phases":545,"briefSummary":547,"conditions":548,"keywords":550,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":4},"100610789","phase-1-clinical-research-on-stem-cell-therapy-for-parkinsons-disease-100610789","NCT07232147","Clinical Research on Stem Cell Therapy for Parkinson's Disease","Clinical Study on the Safety, Tolerance and Preliminary Efficacy of Human Mesenchymal Stem Cell Therapy for Parkinson's Disease","Inclusion Criteria:\n\nThe participants must meet all of the following criteria to be included in this study:\n\n1. The participants must fully understand and comply with the research procedures, voluntarily participate in the study and sign the informed consent form;\n2. At the time of signing the informed consent, the participants must be aged 18 or above and under 75 years old, with no gender restrictions;\n3. During the screening process, the participants must have had primary Parkinson's disease for at least 5 years, have a confirmed medical history record and meet the diagnostic criteria for primary Parkinson's disease as defined by the International Parkinson and Movement Disorder Society (MDS);\n4. During the screening, according to the MDS-UPDRS scoring scale, the Hoehn-Yahr classification of the \"off\" period of drug treatment is 2 to 4;\n5. During the screening, the score of the third part of the MDS-UPDRS in the \"off\" period must be greater than 30;\n6. During the screening, the stable duration of Parkinson's disease and the stable duration of the optimized drug dosage must be at least 4 weeks, and the duration of levodopa use must be at least 1 year;\n7. During the screening, the participants must have a response to levodopa treatment, and the levodopa loading test must be positive;\n8. The participants must experience a decline in the efficacy of anti-Parkinson's disease treatment, which affects their quality of life;\n9. The participants must have good compliance and be able to cooperate with the completion of the assessment items of the trial; For participants with reproductive potential and their partners, they must be free from pregnancy plans for at least 2 weeks before the screening to at least 1 year after the administration of the drug, and must agree to take effective non-drug contraceptive measures during the trial (such as condoms, non-drug intrauterine devices, etc.), except for those who have taken permanent contraceptive measures, such as bilateral tubal ligation, vasectomy, etc.\n\nExclusion Criteria:\n\nIf the subjects meet any of the following criteria, they will not be included in this study:\n\n1. Allergic to the study drug or its excipients, or allergic to similar drugs of the study drug, or have a history of severe allergies (including any food allergy or drug allergy);\n2. Have a previous history of mental disorders, serious diseases, or other significant diseases that may affect safety;\n3. Have a known history of human immunodeficiency virus (HIV) infection (HIV 1\u002F2 antibody positive), or acquired immunodeficiency syndrome-related diseases, or positive HIV serological test results;\n4. Positive for hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV-Ab), or Treponema pallidum antibody positive;\n5. Previously diagnosed with secondary or atypical Parkinson's syndrome caused by drugs, metabolic disorders, or other reasons;\n6. Previously diagnosed with epilepsy, stroke, multiple sclerosis, poorly controlled or progressive neurological diseases;\n7. Have new or unstable mental symptoms within 1 year before screening (such as mental confusion, severe depression, or tendencies towards self-harm\u002Fsuicide);\n8. Have a history of dementia or severe cognitive dysfunction; or have obvious dementia or cognitive dysfunction at screening; the 1.1 part of the MDS-UPDRS score at screening is \\> 3; due to dementia, the subject's compliance is affected, diary cannot be accurately recorded, and\u002For the informed consent cannot be signed;\n9. Have other serious systemic diseases at the time of screening;\n10. Have any history of malignant tumors in the past;\n11. Are participating in other clinical trials, or have participated in other clinical studies within 3 months before administration and received intervention treatment;\n12. Have active infections at the screening period, and still need systemic application of antibiotics, antifungal, antiviral treatment at baseline and the infection has not been controlled;\n13. Have a history of stroke, unstable angina pectoris, or myocardial infarction attack within 6 months before screening;\n14. Have a history of schizophrenia or other severe mental disorders, drug or alcohol abuse;\n15. Pregnant or lactating women; Subjects deemed unsuitable for participation in the study by the investigator's comprehensive assessment.","75 Years",{"count":544,"type":20},20,[546],"PHASE1","This study, through different administration methods, adopted a randomized, double-blind, placebo-controlled trial design to evaluate the safety and tolerability of human umbilical cord mesenchymal stem cells (hUC-MSCs) in patients with Parkinson's disease, explore their initial effectiveness and the relationship between biological active factors and therapeutic efficacy. The \"Clinical Study on the Treatment of Parkinson's Disease with Human Umbilical Cord Mesenchymal Stem Cells\" of this study is expected to provide clinical trial evidence for the development of safe and effective clinical cell therapies for patients with Parkinson's disease.",[549,324,28],"Parkinson Disease (PD)",[551,552,553,554],"Parkinson's disease(PD)","Umbilical cord mesenchymal stem cells (hUC-MSCs)","Stem cell therapy","Safety and efficacy","2025-11-13",{"date":557,"type":33},"2025-11-18",{"date":559,"type":20},"2025-12-01",{"date":561,"type":20},"2027-12-31",{"name":563,"class":40},"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.",{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":17,"minAge":247,"maxAge":221,"enrollmentInfo":570,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":572,"conditions":573,"keywords":578,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":72},"100590462","registry-and-natural-history-of-epilepsy-dyskinesia-syndromes-100590462","NCT06967727","Registry and Natural History of Epilepsy-Dyskinesia Syndromes","Inclusion Criteria:\n\n* Having at least one pathogenic or likely pathogenic variant in one of the genes of interest:\n\nAARS2, ADCY5, ALG13, AP3B2, AP4B1, AP4E1, AP4M1, AP4S1, ARX, ATP1A3, CACNA1A, CACNA1E, CACNA2D2, CDKL5, CSTB, DARS2, DLAT, DLD, DNM1, EARS2, EPG5, EPM2A, FARS2, FOXG1, FRRS1L, GABRA1, GABRA2, GABRB2, GABRB3, GABRG2, GNAO1, GRIA2, GRIA4, GRIN1, GRIN2A, GRIN2B, GRIN2D, HARS2, HNRNPU, HTT, IQSEC2, IRF2BPL, KCNA2, KCNB1, KCNC1, KCNMA1, KCNQ2, KCNQ3, KCNT1, LARS2, MECP2, MEF2C, MTND5, MTTK, MTTL1, NARS2, NHLRC1, PCDH12, PCDH19, PDE10A, PDE2, PDHA1, PDHB, PDHX, PDK3, PDP1, PIGA, PIGN, PIGP, PIGQ, PIGS, PLCB1, POLG, PRRT2, PURA, RHOBTB2, SCN1A, SCN1B, SCN2A, SCN8A, SCN9A, SETBP1, SETD5, SLC13A5, SLC1A2, SLC25A22, SLC2A1, SMC1A, SNX14, SPTAN1, ST3GAL3, STXBP1, SYNGAP1, SYNJ1, SZT2, TARS2, TBC1D24, UBA5, UBE3A, VAMP2, VARS2, WARS2, WDR45, WWOX, YIF1B, YWHAG, and other genes associated with epilepsy-dyskinesia syndromes.\n\nExclusion Criteria:\n\n* Not having a pathogenic or likely pathogenic variants in the genes of interest",{"count":571,"type":20},700,"The Registry and Natural History of Epilepsy-Dyskinesia Syndromes is focused on gathering longitudinal clinical data as well as biological samples (blood, urine, and\u002For skin\u002Ftissue) from male and female patients, of all ages, who have a genetic diagnosis of epilepsy-dyskinesia syndromes. Through prospective review and molecular data analysis, the study aims to identify patterns and correlations between movement and seizure disorders, uncovering genotype-phenotype relationships. The initiative's goals are to enhance understanding of epilepsy-dyskinesia syndromes, inform precision medicine approaches, and foster international collaboration.",[574,288,575,576,577,251,284,256,255,285,286,287,289,28],"Epilepsy-Dyskinesia","Dyskinesia","EDS","Epilepsy-Dyskinesia Syndomes",[265,574,579,575,206,292,293,294,295,300,296,297,298,299,301,302,303,304,305,580],"Epilepsy-Dyskinesia Syndrome","ADCY5","2025-08-15",{"date":583,"type":33},"2025-08-17",{"date":585,"type":33},"2025-06-01",{"date":587,"type":20},"2030-07",{"name":273,"class":71},{"id":590,"slug":591,"hasResults":12,"nctId":592,"briefTitle":593,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":598,"conditions":599,"keywords":604,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":618},"100589740","neuroimmunology-registry-and-biobank-100589740","NCT06958341","Neuroimmunology Registry and Biobank","Registry for Patients With Antibody-mediated Neuroimmunological Diseases","Inclusion Criteria:\n\n1. Differential diagnosis: suspected neuroimmunological disease in which a lumbar puncture is indicated for further diagnosis and treatment decision\n2. Individuals with unclear clinical diagnosis where additional CSF is to be collected for isolation of B cells and production of monoclonal antibodies. The clinical condition of the patients and his\u002Fher compliance have to allow an extra 2-3 ml of CSF to be collected.\n3. Age: all age groups\n4. Gender: patients of both sexes will be included\n\nExclusion criteria:\n\n\\[1\\] Withdrawal of consent",{"count":597,"type":20},300,"A variety of antineuronal antibodies have been detected in the cerebrospinal fluid (CSF) of patients with neurological diseases. This raises the question of whether these antibodies are disease-specific or merely an epiphenomenon of inflammatory processes in the brain.\n\nThe registry was established with the following objectives: \\[1\\] Are antineuronal antibodies much more common than previously thought in various neurological disorders for which the etiology has not yet been elucidated? \\[2\\] Can further correlations, such as those between HSV infection and NMDA receptor autoimmunity, be identified? \\[3\\] Are these antibodies mainly non-specific epiphenomena or are they crucial for the pathogenesis? \\[4\\] What is the clinical course of patients with antineuronal antibodies and their response to therapy? These questions will be addressed in a broad immunohistological screening of a large number of CSF samples and a clinical database of patients with neurological disorders.",[600,601,602,288,28,603,329,287],"Encephalopathy","Psychosis","Impaired Consciousness","Motor Neuropathy",[605,606,607,608],"neuroimmunological diseases","cerebrospinal fluid","cell-based assay","tissue-based assay","2025-05-03",{"date":611,"type":33},"2025-05-06",{"date":613,"type":33},"2021-02-01",{"date":615,"type":20},"2031-07-01",{"name":617,"class":71},"Charite University, Berlin, Germany",2,{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":4,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":17,"minAge":626,"maxAge":627,"enrollmentInfo":628,"targetDuration":4,"studyType":51,"phases":629,"briefSummary":631,"conditions":632,"keywords":643,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":72},"100588946","phase-1-safety-and-efficacy-of-aav9ap4b1-bfb-101-for-patients-with-ap4b1-related-hereditary-spastic-paraplegia-type-47-spg47-100588946","NCT06948019","Safety and Efficacy of AAV9\u002FAP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)","Safety and Efficacy of AAV9\u002FAP4B1 For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47): A Phase 1\u002F2 Single-Center, Open-Label Study of Stereotactic Intra-cisterna Magna Administration","Inclusion Criteria:\n\n1. Male and females between the ages of 12 months - 5 years at the time of treatment\n2. A molecularly confirmed diagnosis of SPG47 (confirmed by a CLIA certified, CE-marked, or equivalent lab): Genomic DNA mutation analysis demonstrating bi-allelic pathogenic variants in the AP4B1 gene.\n3. Proband must have features of neurologic dysfunction by clinical history and physical examination.\n4. Stable doses of concomitant medications such as anti-spasticity medications, anti-epileptic medications, behavioral management medications, sleep medications, and special diets, supplements or nutritional support for at least 3 months prior to Screening. If recent changes (\\\u003C 3 months) in medications, the participant may be allowed per Investigator judgement.\n5. Proband must be fully vaccinated per Centers for Disease Control recommendations for childhood vaccinations.\n6. Two competent custodial parents\u002Fguardians with legal capacity (legally acceptable representatives) to execute an Institutional Review Board\u002FIndependent Ethics Committee (IRB\u002FIEC) approved consent for medical research must be able to participate in the consent process. If only one parent has sole custody to consent for medical research, then that parent must be able to actively participate in the consent process.\n7. Legally acceptable representatives must be able to attend all scheduled study visits and provide feedback regarding the participant's symptoms and performance as described in the protocol.\n8. Legally acceptable representatives agree not to post any of the participant's personal medical data or information related to the study on any website or social media site (e.g., Facebook, Instagram, Twitter, YouTube, etc.) until notified that the study is completed.\n9. Proband and the proband's family must demonstrate ability to travel to the study center. For the first 30 days post treatment probands will need to stay within a 100-mile radius from the treatment center.\n\nExclusion Criteria:\n\n1. Inability to participate in the clinical evaluation as determined by the principal investigator.\n2. Clinically significant abnormal laboratory values (hemoglobin \\\u003C 8 or \\> 20 g\u002FdL; white blood cell \\> 20,000 per cmm, platelets count \\\u003C 100,000 per cmm; international normalized ratio \\[INR\\] \\> upper limit of normal \\[ULN\\]; gamma-glutamyl transferase \\[GGT\\], alanine aminotransferase \\[ALT\\], and aspartate aminotransferase \\[AST\\] or total bilirubin \\> 1.5 × ULN, creatinine\n\n   ≥ 1.5 mg\u002FdL) prior to gene replacement therapy.\n3. Presence of a concomitant medical condition that precludes a cisterna magna or lumbar puncture or use of anesthetics for sedated procedures.\n4. Bleeding disorder or any other medical condition or circumstance in which a cisterna magna or lumbar puncture is contraindicated according to local institutional policy.\n5. Documented cardiomyopathy or significant congenital heart abnormalities.\n6. Inability to be safely sedated in the opinion of the clinical anesthesiologist.\n7. History of severe\u002Flife-threatening allergic reaction to sirolimus, tacrolimus, corticosteroids, or gadolinium.\n8. Any known history and\u002For family history of hemophagocytic lymphohistiocytosis (HLH) or multisystem inflammatory syndrome (MIS)\n9. Concomitant illness or requirement for chronic drug treatment that in the opinion of the investigator creates unnecessary risks for gene transfer.\n10. Concomitant chronic drug treatment that would cause clinically significant interactions with immunosuppressive agents used in the study.\n11. Any item which would exclude the participant from being able to undergo magnetic resonance imaging (MRI) according to local institutional policy.\n12. Any other situation that would exclude the participant from undergoing any other procedure required in this study.\n13. Visual or hearing impairment sufficient to preclude cooperation with neurodevelopmental testing.\n14. The presence of significant non-SPG47 related central nervous system (CNS) impairment or behavioral disturbances that would confound the scientific rigor or interpretation of results of the study.\n15. Recent or planned elective surgical procedures that would confound the scientific rigor or interpretation of results of the study, as determined by the Investigator\u002Fstudy team.\n16. Failure to obtain appropriate informed consent.\n17. Reason to believe that the participant or parents\u002Fguardians of the participant will not comply with the study procedures outlined in the study protocol.\n18. Receiving a live vaccine within 30 days prior to gene transfer.\n19. Receiving an investigational drug within 30 days prior to screening or plan to receive an investigational drug (other than gene therapy) during the study.\n20. Enrollment and participation in another interventional clinical trial.","12 Months","60 Months",{"count":238,"type":20},[546,630],"PHASE2","Safety and Efficacy of AAV9\u002FAP4B1 For Patients with AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47): A Phase 1\u002F2 Single-Center, Open-Label Study of Stereotactic Intra-cisterna Magna Administration.\n\nThe goal of this clinical trial is to evaluate whether a gene therapy can safely treat children with SPG47, a rare genetic condition that causes progressive spasticity and developmental delays. The main questions it aims to answer are:\n\n* Is the gene therapy safe and well tolerated?\n* Does the gene therapy improve motor function and developmental outcomes?\n\nParticipants will:\n\n* Undergo screening assessments to confirm eligibility\n* Receive a single dose of the gene therapy vector\n* Attend follow-up visits for safety monitoring and developmental assessments over the course of five years",[633,323,634,635,636,637,638,335,639,640,641,28,642],"HSP","Hereditary Spastic Paraparesis","Hereditary Spastic Paraplegia Type 50","Hereditary Spastic Paraplegia Type 47","Hereditary Spastic Paraplegia Type 51","Hereditary Spastic Paraplegia Type 52","AP4B1","Neurogenetic Disorders","Neurodevelopmental Conditions","Gene Therapy",[633,323,635,636,637,638,634,329,642,644,335,639,645,646,647,206,648,649],"AAV9","AP4M1","AP4E1","AP4S1","neurogenetic conditions","neurodevelopmental conditions","2025-04-22",{"date":652,"type":33},"2025-04-28",{"date":654,"type":20},"2025-08",{"date":656,"type":20},"2032-08",{"name":658,"class":40},"BlackfinBio Ltd",{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":664,"acronym":665,"eligibilityCriteria":666,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":667,"targetDuration":4,"studyType":51,"phases":669,"briefSummary":670,"conditions":671,"keywords":672,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":678,"lastUpdatePostDateStruct":679,"startDateStruct":681,"completionDateStruct":683,"leadSponsor":685,"locationsCount":72},"100427597","stepwise-parkinson-a-smartphone-based-exercise-solution-for-patients-with-parkinsons-disease-100427597","NCT04848077","STEPWISE Parkinson: A Smartphone Based Exercise Solution for Patients With Parkinson's Disease","STEPWISE Parkinson: A Smartphone Based, Titrated Exercise Solution for Patients With Parkinson's Disease in Daily Life","STEPWISE","Inclusion Criteria:\n\n* idiopathic PD\n* Hoehn and Yahr 1-3\n* able to understand the Dutch language\n* able to walk independently\n* equal to or less than 120 minutes of sports\u002Foutdoor activities per day (question 5-28 LASA Physical Activity Questionnaire (LAPAQ))\n* less than 7,000 steps\u002Fday during 1-month baseline (week -4 until 0)\n\nExclusion Criteria:\n\n* weekly falls in the previous 3 months\n* medical conditions that hamper mobility other than PD\n* living in a nursing home\n* cognitive impairments that hamper use of the motivational app (subjective evaluation by the assessor)\n* not in the possession of a suitable smartphone (Iphone 5S or newer with iOS 10 or higher or Android 4.1 or newer)",{"count":668,"type":20},452,[53],"The aim of this study is to investigate whether a smartphone app can increase physical activity in patients with Parkinson's Disease in daily life for a long period of time (12 months).",[28,25],[673,674,675,25,676,677],"Physical activity","Walking","Exercise","Locomotion","Motivational application","2025-04-16",{"date":680,"type":33},"2025-04-20",{"date":682,"type":33},"2021-05-18",{"date":684,"type":20},"2026-09",{"name":686,"class":71},"Radboud University Medical Center",{"id":688,"slug":689,"hasResults":12,"nctId":690,"briefTitle":691,"officialTitle":692,"acronym":693,"eligibilityCriteria":694,"healthyVolunteers":12,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":695,"targetDuration":4,"studyType":51,"phases":697,"briefSummary":698,"conditions":699,"keywords":702,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":704,"lastUpdatePostDateStruct":705,"startDateStruct":707,"completionDateStruct":709,"leadSponsor":711,"locationsCount":72},"100577563","possibilities-of-use-mri-guided-laser-interstitial-thermal-therapy-in-medically-intractable-tremor-100577563","NCT06799923","Possibilities of Use MRI-Guided Laser Interstitial Thermal Therapy in Medically Intractable Tremor","Possibilities of Use Magnetic Resonance Imaging (MRI)-Guided Laser Interstitial Thermal Therapy (LITT) in Treatment of Medically Intractable Tremor","PossibiLITT","Inclusion Criteria:\n\n* Patients 18 years age or older with Parkinson\\'s disease or essential tremor and tremor resistant to medical therapy with a contraindication to deep brain stimulation or refusal deep brain stimulation\n\nExclusion Criteria:\n\n* Contraindication to MRI\n* Contraindication to general anesthesia\n* Patient unable to give their free and informed consent because of cognitive or psychiatric disorders\n* Brain anatomical abnormalities not allowing intervention\n* Adults protected (guardianship, curators) or deprived of liberty.",{"count":696,"type":20},15,[53],"Medically intractable tremors are a common difficult clinical situation. Deep brain stimulation decreases Parkinson's disease tremor and essential tremor, but not all patients are candidates from a diagnostic, medical, or social standpoint, prompting the need for alternative surgical strategies. Less invasive lesional brain surgery (thalamotomy) procedures by radio-surgery or MRI-guided focused ultrasound have emerged and have proven to be effective in these third-line indications. Recently, a new technology has emerged allowing the performance of minimally invasive lesion surgeries by MRI-Guided Laser Interstitial Thermal Therapy (MRIg-LITT). MRIg-LITT has been shown to be effective and safe in management of epilepsies and brain tumors. However, no study has evaluated MRIg-LITT for performing thalamotomy in medically intractable tremor.In a pilot study, the investigators propose to evaluate the effect and safety of unilateral thalamotomy by MRIg-LITT in the management of medically intractable tremor of parkinsonian or essential origin.",[700,25,27,28,701],"Laser Interstitial Thermal Therapy","MRI",[703,25,27,28,701],"laser interstitial thermal therapy","2025-01-28",{"date":706,"type":33},"2025-01-29",{"date":708,"type":33},"2024-08-01",{"date":710,"type":20},"2026-04",{"name":712,"class":71},"Centre Hospitalier Universitaire, Amiens",{"id":714,"slug":715,"hasResults":12,"nctId":716,"briefTitle":717,"officialTitle":717,"acronym":4,"eligibilityCriteria":718,"healthyVolunteers":110,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":719,"targetDuration":720,"studyType":22,"phases":4,"briefSummary":721,"conditions":722,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":723,"lastUpdatePostDateStruct":724,"startDateStruct":726,"completionDateStruct":728,"leadSponsor":729,"locationsCount":72},"100549612","handwriting-analysis-in-movement-disorders-100549612","NCT06436287","Handwriting Analysis in Movement Disorders.","Inclusion Criteria:\n\n(1) Diagnosed with a movement disorder.\n\nExclusion Criteria:\n\n1. Action tremor or weakness in the dominant hand interfering with writing task.\n2. Unable to write or understand English",{"count":186,"type":20},"1 Day","Movement disorders are a group of neurological conditions that cause problems with movement, either in the form of excessive, reduced, or slow movements. Some commonly known movement disorders include Parkinson disease, dystonia, ataxia, and Tourette syndrome. Multiple movement disorders have unique handwriting characteristics that can be measured using an inkless pen and a digitalized tablet. Handwriting is a complex skill that requires a combination of cognition, motor planning, and visuomotor integration. Handwriting deteriorates in patients with neurodegenerative diseases.\n\nThis study aims to discern variations in the kinematics (movement patterns) involved in handwriting between individuals with movement disorders and healthy controls. Participants will be invited to carry out a series of handwriting tasks. The pen motions will be captured using an inkless pen and a digitizing tablet linked to a laptop. The entire set of tasks is designed to be completed within 30 minutes. The data will then be collected, processed, and analyzed utilizing a handwriting analysis software.",[28],"2025-01-21",{"date":725,"type":33},"2025-01-24",{"date":727,"type":20},"2025-01",{"date":587,"type":20},{"name":730,"class":71},"Western University, Canada"]